Poxel News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.02.20	Poxel Reports Financial Update for Cash and Revenue for the Full Year 2019 and Provides Corporate Update (Businesswire)
12.02.20	Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress (Businesswire)
23.01.20	Poxel Appoints Industry Leader Dr. David E. Moller as Chief Scientific Officer (Businesswire)
08.01.20	Poxel Announces its Financial Calendar for 2020 (Businesswire)
19.12.19	Poxel Announces Participation at ODDO BHF Forum (Businesswire)
18.12.19	Poxel Announces Positive Results for PXL065 Phase 1b Trial and Provides Program Update (Businesswire)
26.11.19	Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan (Businesswire)
12.11.19	Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019 (Businesswire)
08.11.19	Poxel Announces Positive Update Following FDA Meeting for PXL065 for Treatment of NASH (Businesswire)
07.11.19	Poxel to Present Results From Phase 1a Study of PXL065 at the Liver Meeting® 2019 (Businesswire)
05.11.19	Poxel Obtains Additional Funding to Advance Pipeline Programs (Businesswire)
18.09.19	Poxel Announces Detailed Imeglimin Phase 3 TIMES 1 Results Presented at 55th Annual Meeting of the European Association for the Study of Diabetes (Businesswire)
17.09.19	Poxel Initiates Phase 1b Multiple Ascending Dose (MAD) Trial for NASH Drug Candidate, PXL065 (Businesswire)
09.09.19	Poxel Announces Symposium Presentation for Imeglimin at 55th Annual Meeting of the European Association for the Study of Diabetes (Businesswire)
04.09.19	Poxel Announces Participation at the H.C. Wainwright 21st Annual Global Investment Conference (Businesswire)
22.08.19	Poxel to Report Half Year Results for 2019 and Host Conference Call on August 26, 2019 (Businesswire)
05.08.19	Poxel Initiates Pharmacokinetic (PK)/ Pharmacodynamic (PD) Study as part of the Phase 2a Clinical Program for PXL770, a Direct AMPK Activator for the Treatment of NASH (Businesswire)
15.07.19	Poxel Reports Financial Update for Cash and Revenue for the Second Quarter and the First Half 2019 and Provides Corporate Update (Businesswire)
09.07.19	Metavant and Poxel Announce Positive Topline Safety and PK/PD Results of Imeglimin in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3b/4 (Businesswire)
25.06.19	Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes (Businesswire)
21.05.19	Poxel Announces Participation at Two Upcoming Investor Conferences and Imeglimin Presentation at the Japanese Diabetes Society (Businesswire)
09.04.19	Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes (Businesswire)
08.04.19	Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial (Businesswire)
08.04.19	Poxel Announces First Quarter 2019 Financial Update (Businesswire)
01.04.19	Poxel Initiates Phase 2a Program for PXL770, a Direct AMPK Activator for the Treatment of NASH (Businesswire)
21.03.19	Poxel Reports Financial Results for Full Year 2018 and Provides Corporate Update (Businesswire)
18.03.19	Poxel Announces Participation at the Oppenheimer 29th Annual Healthcare Conference (Businesswire)
11.03.19	Poxel to Report Full Year 2018 Financial Results and Host Conference Call on March 21, 2019 (Businesswire)
12.02.19	Poxel Announces Fourth Quarter and Full Year 2018 Financial Update (Businesswire)
07.01.19	Poxel Announces Presentation of PXL065 Data at the 2019 NASH-TAG Conference (Businesswire)
26.11.18	Poxel Announces Initiation of Part 2 of Phase 1a Study for PXL065, which is being Developed for the Treatment of NASH (Businesswire)
12.11.18	Poxel Presents Promising Data for PXL770 and PXL065 for the Treatment of NASH at the American Association for the Study of Liver Diseases Meeting (Businesswire)
08.10.18	Poxel Announces Completion of Patient Enrollment for TIMES 2 Trial in Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
04.10.18	Poxel Presents Complete PXL770 Phase 1 Results, Cardiac Safety Profile and Preclinical Efficacy Data in NASH at AMPK - From Mechanisms to New Therapies Scientific Congress (Businesswire)
19.09.18	Poxel Reports Financial Results for the First Half 2018 and Provides Corporate Update (Businesswire)
13.09.18	Poxel Appoints Takashi Kaneko, MD, PhD, as Senior Vice President Medical and President of Poxel Japan K.K. (Businesswire)
30.08.18	Poxel Expands Metabolic Pipeline Through Strategic Acquisition Agreement with DeuteRx for DRX-065, a Novel Clinical Stage Drug Candidate for NASH, and Other Programs (Businesswire)
28.08.18	Poxel Announces Completion of Patient Enrollment for the TIMES 3 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
18.07.18	Poxel Announces Favorable Results for PXL770 Phase 1b Multiple Ascending Dose Trial and Drug-Drug Interaction Study (Businesswire)
10.07.18	Poxel Announces Second Quarter and First Half 2018 Financial Update (Businesswire)
25.06.18	New Imeglimin Data Demonstrating Pancreatic Beta-Cell Protection Presented at the American Diabetes Association 78th Scientific Sessions (Businesswire)
23.04.18	Poxel Announces First Quarter 2018 Financial Update (Businesswire)
04.04.18	Poxel Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference (Businesswire)
22.03.18	Poxel Provides Business Update and Reports Results for Full Year 2017 (Businesswire)
15.03.18	Poxel to Report Full Year 2017 Results on March 22, 2018 After Market Close and Host Conference Call at 7:00 PM CET (Paris time) / 2:00 PM EDT (New York time) (Businesswire)
13.03.18	Poxel Announces Initiation of TIMES 2 and TIMES 3 Trials for the Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan (Businesswire)
07.03.18	Poxel Announces Participation at the Cowen 38th Annual Healthcare Conference and Oppenheimer 28th Annual Healthcare Conference (Businesswire)
27.02.18	Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018 (Businesswire)
12.02.18	Roivant and Poxel Announce Strategic Agreement for Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries Worldwide (Businesswire)
22.01.18	Poxel Announces Fourth Quarter 2017 Financial Update (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Poxel SA

Aktien Top/Flop

Meistgelesene Nachrichten